Archive for the NanOlogy in the News Category

Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm

Drug Delivery: NanOlogy Touts Preclinical Data for Inhaled NanoPac Cancer Drug

Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer

BioCentury: Tiny Taxanes – How Nanology’s Particle Production Technology Created Submicron Chemotherapy

Drug Delivery: NanOlogy looks to transform chemotherapy with localized delivery platform

Drug Development: NanOlogy Submicron Particle Platform Transforms Systemic Chemotherapy Into Local Delivery

DermWire: NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastases

Houston Business Journal: NanOlogy to Update Clinical Program at BIO CEO Conference

PharmaVOICE: Next-Generation Nanomedicines

Drug Delivery Business: NanOlogy takes nanoparticle tech into Phase II trials

Clinical Leader: Trial Aims To Kill Cancer Without Chemotherapy Side Effects

DDNEWS: New Cancer Answer

Ovarian Cancer News: First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery

Journal for Clinical Studies: NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer

Drug Delivery: NanOlogy takes nanoparticle tech into phase 2 trials.

PBR: NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer

Practical Dermatology: Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AK

DFB Pharmaceuticals Forms NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform

Cancer Treatment: DFB Pharmaceuticals forms new company that could revolutionize cancer treatment

‘Bare’-ish on naked effort, Nanology unveils particle approach across cancers

Follow Us

(817) 900-4002
3909 Hulen Street
Fort Worth, Texas 76107